Share on facebook Share on Twitter Share on Google Plus Share This

Research and Clinical Trials

Laboratory and Translational Research in the John C. Davis Program

Translational studies are a fundamental aspect of the modern treatment of plasma cell diseases. A major focus of our research is identifying the genes and proteins that enable malignant plasma cells to survive despite modern treatments and to develop new ways to inhibit those key survival factors. We also provide the opportunity for newly diagnosed patients to have minimal residual disease studies performed once they achieve complete responses with therapy. Minimal residual disease studies will help us further characterize the effectiveness of therapy and the durability of complete responses.

Our research staff handles the bone marrow, blood and stem cells of patients willing to donate to advance our knowledge these diseases. For minimal residual disease testing we employ a state-of-the-art genetic test that is performed on bone marrow cells from diagnosis and at the time of achieving a complete response.

Clinical Trials

These clinical trials are currently open and recruiting patients at Tufts:

For multiple myeloma:

An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax® CD38)(Anti-CD38 Monoclonal Antibody) in Combination with Backbone Regimens for the Treatment of Subjects with Multiple Myeloma

IRB # 11159

Sponsored by Janssen Biotech

Alternate study arm available: HuMax® CD38 (Daratumumab) + Carfilzomib-Revlimid-Dexamethasone regimen

Phase 2b Open-Label Single-Arm Selinexor (KPT-330) + Low-Dose Dexamethasone in Patients w/ Multiple Myeloma Quad-refractory to Previous Therapies (STORM)

Sponsored by Karyopharm

E1A11: Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma

IRB # 105

Sponsored by Eastern Cooperative Oncology Group (ECOG)

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma

IRB # 111

Sponsored by Eastern Cooperative Oncology Group (ECOG)

A Study of Oral Ixazomib Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma Not Treated with Stem Cell Transplantation

Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155)

IRB # 12176

Sponsored by Merck Sharp & Dohme Corp

For systemic AL amyloidosis

A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early

IRB# 12016

Sponsored by the Principal Investigator

PRONTO: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction

Sponsored by Prothena Therapeutics Ltd.

Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients with AL Amyloidosis

IRB #11829

Sponsored by the Principal Investigator

A Phase 3, Randomized, Controlled, Open-Label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician’s Choice of Treatment Administered to Patients with Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

IRB # 1135836

Sponsored by Millennium Pharmaceuticals

Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients with Relapsed ALAmyloidosis

IRB # 10694

Sponsored by Columbia University Medical Center

A Phase 1/2, Open Label, Dose Escalation Study of Intravenous Administration of Single Agent NEOD001 in Subjects with Light Chain (AL) Amyloidosis

IRB # 10756

Sponsored by Prothena Therapeutics Ltd.

The Vital Amyloidosis Study, a Phase 3, Multicenter Efficacy and Safety Study of NEOD001

Sponsored by Prothena Therapeutics Ltd.